Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Locus Pharmaceuticals and Novartis enter into research collaboration

Locus Pharmaceuticals has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

UsiRNA reduces tumor growth in vivo

MDRNA, Inc. (NASDAQ: MRNA) presented new in vivo data showing continued progress in the advancement of the Company’s oncology program. J. Michael French, President and CEO, reported that MDRNA’s UsiRNAs, delivered by the Company’s DiLA2 platform, down-regulated a previously “non-druggable” target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Medicago awarded U.S. Army contract

Medicago Inc. (TSX-V: MDG) has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center (“ECBC”) Research & Technology Directorate. Medicago will work with ECBC to investigate the affordable production of industrial enzymes in the field of biofuels. This new project builds on Medicago’s proprietary plant-based manufacturing platform and its potential for applications beyond the biological drug market. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Hana Biosciences completes private placement

Hana Biosciences (OTCBB:HNAB) has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million. Net proceeds of the offering will be used to support completion of Hana’s pivotal Phase 2 clinical trial (rALLy) of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Podcast with Joyce Cramer, Epilepsy Therapy Project

Biotech-Now’s Tracy Krughoff speaks with Joyce Cramer, president of the Epilepsy Therapy Project about the upcoming BIO Investor Forum and what this advocacy group looks for in terms of companies and projects. Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,